AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05364567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
Study NCT01346631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paleolithic diet
Description: The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
Study NCT02597335 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spectro-MRI
Description: Spectro-MRI for D-2HG detection
Study NCT02597335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dosage of free circulating plasmatic DNA
Study NCT02597335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dosage of D-2HG in the urine
Study NCT02567760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP1
Description: Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
Study NCT02567760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive Placebo drink after meal for 8 weeks.
Study NCT01004887 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT00894400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: catheter ablation using radiofrequency energy
Study NCT00894400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation using radiofrequency energy
Study NCT04318106 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Precision tinted spectacle lenses
Description: Precision tinted spectacles lenses (Cerium Technologies TM)
Study NCT04318106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision tinted spectacle lenses
Description: Precision tinted spectacles lenses (Cerium Technologies TM)
Study NCT01027052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hamburger meat patty with salt
Description: hamburger meat cooked with salt
Study NCT01027052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamburger meat patty with spice blend
Description: hamburger meat cooked with spice mixture
Study NCT03572647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eritromax
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Study NCT03572647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprex
Description: The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
Study NCT03997175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodiversity powder
Description: Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
Study NCT03997175 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sand that looks like intervention sand but does not have high biodiversity
Study NCT00540462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Study NCT00540462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Study NCT00429013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Display Unit
Description: lingual electric stimulation
Study NCT04226989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-RD06
Description: CT-RD06 cell injection by intravenous infusion
Study NCT01619189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epithelial stem cells cultured
Description: transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
Study NCT01619189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of cultured cells
Description: transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
Study NCT02747823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT124
Description: 1 mg/kg IV infusion
Study NCT02747823 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU Sourced Avastin®
Description: 1 mg/kg IV infusion
Study NCT02747823 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Sourced Avastin®
Description: 1 mg/kg IV infusion
Study NCT01225653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Topical application
Study NCT01225653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost
Description: Topical application
Study NCT00004139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00004139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00004139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT01376453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
Study NCT01376453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.
Study NCT01376453 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation sessions will be daily, Monday through Friday, except for holidays.
Study NCT04315753 — intervention group
Intervention type: OTHER
Intervention: LDCT (Low Dose CT)
Description: validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
Study NCT01997905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriClip LAA Exclusion Device
Study NCT02259660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength training
Description: Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
Study NCT02259660 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham respiratory muscle strength training
Description: The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
Study NCT03416322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange
Description: Infusion and remove water during inertion and withdrawal of colonoscope
Study NCT02354820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence Based Constipation Reminders
Study NCT02706405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
Description: Given IV
Study NCT02706405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02706405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02706405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04078971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: Subjects in this intervention will follow a normal western diet
Study NCT04078971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Subjects in this group will follow a low carbohydrate ketogenic diet
Study NCT01409239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Description: 24 hr IV insulin administered according to hospital guideline
Study NCT01409239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: basal bolus insulin using carb counting technique and insulin analogues
Study NCT00640770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon angioplasty
Description: balloon angioplasty
Study NCT00640770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug eluting stent
Description: Cypher Select+ Coronary or Infrapopliteal Stent
Study NCT03081364 — intervention group
Intervention type: OTHER
Intervention: Initiate ACLS protocol if lethal arrythmia develops
Description: Cardiac Rhythm Management
Study NCT03789175 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nicotinamide Riboside (NR)
Description: Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
Study NCT03061422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: caries prevention chewing gum
Study NCT02983890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dicloxacillin
Description: Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned
Study NCT02983890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned
Study NCT06609122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: Animal-assisted intervention (AAI) is a therapeutic approach that involves animals as part of a treatment plan to improve physical, social, emotional, or cognitive functioning in individuals. Animals such as dogs, cats, horses, and even dolphins are commonly used in AAI due to their ability to provide comfort, companionship, and motivation.~AAI can take many forms, including animal-assisted therapy (AAT), where a trained therapy animal works with a licensed healthcare professional to achieve specific treatment goals. Animal-assisted activities (AAA) involve interactions with animals in a more casual and recreational setting, such as visits to hospitals or nursing homes to provide companionship and emotional support.
Study NCT03061422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xylitol with bicarbonate
Description: caries prevention chewing gum
Study NCT03061422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paraffin
Description: chewing gum
Study NCT02292862 — intervention group
Intervention type: PROCEDURE
Intervention: Lymph node and blood sampling
Description: By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant.
Study NCT00603525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
Study NCT00603525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
Study NCT02032589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-generation treatment
Description: self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
Study NCT02894970 — intervention group
Intervention type: DEVICE
Intervention: Pulmonary PPG
Description: Five minutes check with a lights source with two wave lengths of infrared and a detector.
Study NCT00264303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: 5mg oral capsules, once daily, 4 week duration
Study NCT00264303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: 5mg oral capsules, once daily, 4 week duration
Study NCT03821103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
Study NCT03821103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic enhanced arm
Description: Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
Study NCT03355339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binasal occlusion
Description: Binasal occlusion glasses
Study NCT03355339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No binasal occlusion
Description: Non-occluded glasses
Study NCT00949000 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD Implantation
Description: Implantation of a commercially available AnalyST or AnalyST Accel ICD
Study NCT02799459 — intervention group
Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: the patient will receive a general anaesthesia do proceed at her conization
Study NCT02799459 — intervention group
Intervention type: PROCEDURE
Intervention: Hypnosis in conization
Description: this is the experimental treatment which is allocated to the experimental group
Study NCT04953598 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: Patient undergoes diagnostic ultrasound examination
Study NCT03255356 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
Study NCT00919633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: subcutaneous continuous infusion at one of three doses for 48 weeks
Study NCT00919633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: 1.5 μg/kg subcutaneous weekly for 48 weeks
Study NCT00919633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin
Study NCT00919633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin, USP
Description: All patients will receive oral ribavirin
Study NCT00919633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external drug infusion pump
Description: pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
Study NCT01409551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS hyperthermic chemoperfusion
Description: VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
Study NCT01409551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bedside talc slurry pleurodesis
Description: Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
Study NCT00732862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose clamp
Description: Hyperinsulinemic Hypoglycemic clamp
Study NCT00732862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hyperinsulinemic Hypoglycemic clamp
Study NCT01507987 — intervention group
Intervention type: DEVICE
Intervention: Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads
Description: Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies
Study NCT01520805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
Study NCT00667225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cantharidin's vehicle
Description: Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
Study NCT02789969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone 15mcg/kg IV
Study NCT02789969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 1.5mcg/kg IV
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: human menopausal gonadotropin subcutaneously
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: human menopausal gonadotropin subcutaneously
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist subcutaneously
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist subcutaneously
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH analog
Description: GnRH analog subcutaneously
Study NCT03291821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH analog
Description: GnRH analog subcutaneously
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trophectoderm biopsy
Description: Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trophectoderm biopsy
Description: Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MitoScore
Description: The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
Study NCT03291821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MitoScore
Description: The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
Study NCT03291821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.